Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novo Nordisk wins...

    Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-23T14:16:19+05:30  |  Updated On 13 Aug 2021 3:20 PM IST

    Novo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.


    New Delhi: The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. Copenhagen-listed shares of the company rose 2.6% in late European trading.


    The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month.


    Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.


    Eli Lilly and Co's Trulicity, an injectable rival, has a list price of $759.40 per month, according to Lilly's website.


    Rybelsus, which will be available in the United States in the fourth quarter, stimulates insulin production in patients with type 2 diabetes, the most common form of the disease, and is meant to be taken once a day.


    Novo is betting on the success of its launch as the company faces pricing pressures from competitors and U.S. lawmakers, who have been critical of rising drug costs.


    The approval makes Rybelsus the first drug of its class on the market that does not have to be injected, an advantage Novo hopes to capitalize on, as it sells to diabetics with an aversion to shots.


    "The oral administration is likely to make oral semaglutide competitive for quite some time," Pareto Securities analyst Johan Unnerus said.


    The closest competition is probably Novo's Ozempic, Lilly's Trulicity and, in some way, Merck & Co Inc's Januvia, he added.


    The brokerage expects Rybelsus sales of at least DKK 36.6 billion ($5.40 billion) in 2026.


    The drug's label comes with a boxed warning, the FDA's harshest, flagging a potential increased risk of thyroid c-cell tumors. It also states that Rybelsus is not recommended as the first choice of medicine for treating diabetes.


    Novo has invested in manufacturing facilities in North Carolina to supply the U.S. market with the oral pill.


    The company said it plans to source initial supply from Denmark, but would manufacture Rybelsus in the United States in future. Novo is also testing semaglutide as a treatment for obesity and non-alcoholic steatohepatitis, a fatty liver disease.


    By Tamara Mathias


    Read Also: Novo Nordisk Tresiba shows a lower risk of hypo in adults with Type 2 Diabetes

    Eli LillyJohan Unnerusliver diseaseMerckNovo Nordiskoral diabetes drugOzempicpharmapharma companypharma newsRybelsussemaglutidesteatohepatitistype-2 diabetesUS approvalUSFDAUSFDA approval
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok